Top 10 AI Prompts and Use Cases and in the Healthcare Industry in Israel

Israel's edge in healthcare AI reads like a systems-level advantage: world‑leading R&D intensity, roughly 1,600 health‑tech firms, and compact national infrastructure where four HMOs have digitized decades of care - over 98% of the population is insured and a majority use the same linked EMR for at least a decade - making clinical validation fast and realistic (Startup Nation Central: Israel Health Tech Ecosystem).

Capital is following: 2024 saw a $1.2B private funding surge across 102 rounds, accelerating clinical AI, device‑plus‑cloud models, and multimodal data projects (Israel Health Tech Investment Surge 2024).

For professionals wanting practical AI skills to join this momentum, Nucamp's AI Essentials for Work bootcamp teaches promptcraft and workflow integration so non‑technical staff can help turn

weeks of pathology review into minutes

and plug into Israeli clinical pilots (Register for Nucamp AI Essentials for Work bootcamp).

Bootcamp	Length	Early Bird Cost	Register
AI Essentials for Work	15 Weeks	$3,582	Register for Nucamp AI Essentials for Work (15‑week bootcamp)

Selection favored Israeli use cases that could be validated, deployed, and governed inside Israel's distinctive ecosystem - where four HMOs hold decades of linked EMRs and clinical pilots move faster than in fragmented markets - so prompts emphasize clinical validation, data governance, and real workflow impact.

Priority criteria included: demonstrable clinical-study readiness (MOH guidance and Medical Information Mobilization/FHIR interoperability are central), alignment with Israel's sector‑based AI rules and the 2023 “Responsible Innovation” policy plus 2025 privacy drafts (Israel AI regulation overview and guidance); clear data‑sharing pathways and privacy controls under national law (Israel digital health laws and regulations 2025 analysis); and market traction tied to Israel's AI growth story and health‑tech density (Startup Nation Central report on Israel's AI ecosystem and healthtech).

The result: prompts and company picks that stress reproducible clinical endpoints, privacy‑aware data pipelines (including federated options), and business models that scale from Israeli pilots - turning long validation cycles into fast, actionable evidence that matters at the bedside.

Zebra Medical Vision packages automated radiology triage and reporting into a scalable, PACS/EHR‑integrated suite that flags urgent findings (intracranial hemorrhage, pneumothorax) and screens for cardiovascular, pulmonary, oncologic and musculoskeletal disease to help radiologists prioritize worklists and shorten time‑to‑treatment (Zebra Medical Vision PACS/EHR-integrated radiology triage product page).

Clinical research releases note a chest X‑ray model trained on nearly 2 million images to identify roughly 40 common findings and multiple CE‑marked algorithms, while press coverage documented a low‑cost AI1 service marketed at $1 per scan to boost hospital throughput (ITN Online article on Zebra Medical Vision chest X‑ray research; AuntMinnie coverage of Zebra's $1-per-scan AI service).

In Israel's EMR‑connected HMOs these real‑time alerts and automated draft reports can convert large backlogs into a short, prioritized queue - making emergent cases stand out immediately without changing core radiology workflows.

“Medical experts worldwide are facing a critical challenge in handling overwhelming demand. We are excited to partner with the Zebra‑Med team, which is harnessing the power of data and machine learning to provide physicians and healthcare systems with tools to dramatically increase capacity, while improving patient care,” said Yair Schindel, M.D., managing partner at aMoon VC.

MeMed BV turns the body's own immune signals into a fast, bedside decision aid: from a small serum or whole‑blood sample the FDA‑cleared MeMed BV host‑response test measures three proteins (TRAIL, IP‑10 and CRP) and delivers a single bacterial‑vs‑viral score in about 15 minutes - roughly the length of a coffee break - so clinicians in Israeli EDs and urgent care can decide whether antibiotics are likely warranted without waiting days for pathogen results (MeMed BV host-response test product page).

Validation includes multi‑center cohorts in Israel and elsewhere and real‑world studies that reported large reductions in unnecessary antibiotic prescriptions; at the same time independent reviewers note a nontrivial false‑negative rate (on the order of ~10%), and MeMed BV is best viewed as an adjunct to clinical judgment rather than a standalone “sepsis” rule‑out tool (PulmCCM evaluation of MeMed BV sepsis test).

For Israeli HMOs and rapid‑response clinics the appeal is clear: actionable clarity at the point of care that can tighten antimicrobial stewardship while preserving pathways to escalated testing when the score and clinical picture diverge.

“Rather than attempting to detect the [individual pathogens], we decided to use the best detection system available... the immune response.”

Nuvo's INVU™ brings physician‑prescribed, FDA‑cleared remote fetal non‑stress tests to the home via a wearable band and mobile app that streamlines data collection and transmits clinician‑ready maternal and fetal signals in real time - reducing staff burden and widening access to prenatal monitoring as the company scales its commercial operations into the US and Israel after its 2024 public listing (HIT Consultant: Nuvo goes public to expand remote pregnancy monitoring).

INVU's device‑plus‑cloud design has already been integrated into virtual maternity workflows through partners like Babyscripts, making it a pragmatic option for clinics seeking to shift routine NSTs out of busy units and toward remote, scheduled monitoring that keeps high‑risk follow‑up pathways intact (Babyscripts partners with Nuvo to integrate INVU remote pregnancy monitoring).

“Nuvo is committed to solving the inherent problems of a broken pregnancy care system by enabling access to quality care with advanced remote monitoring technology,” said Rice Powell, CEO of Nuvo.

IR‑MED (PressureSafe) sits in the same practical lane as the bedside sensors the literature highlights: tools that sense tissue changes beneath intact skin so clinicians in Israel's HMOs and long‑term care units can act before a visible ulcer appears.

Systematic review evidence singles out subepidermal moisture (SEM) devices as the most consistent early detector - able in some studies to flag pressure‑related changes up to a week before skin breakdown - while near‑infrared spectroscopy (NIRS) is now gaining attention for its promise in equitable deep‑tissue injury detection across darker skin tones (systematic review of bedside detection technologies for pressure injuries; near-infrared spectroscopy for equitable deep tissue injury detection).

For Israeli care pathways that already digitize workflows, these portable, quick tools offer a clear

“so what?”

earlier, objective signals that can shift staffing and prevention resources away from costly wound care toward targeted repositioning, offloading, and escalation only when needed - improving outcomes and fairness in a diverse patient population.

Technology	Evidence Strength	Clinical Takeaway
Subepidermal Moisture (SEM)	Strongest, consistent	Predicts PrE/stage‑1 PI up to ~1 week; high interrater reliability
Near‑Infrared Spectroscopy (NIRS)	Promising (equity focus)	May detect deep tissue compromise across skin tones
Thermography	Mixed	Temperature changes inconsistent; ambient factors matter
Ultrasound	Potential but variable	Detects subcutaneous hypoechoic lesions; operator dependent
Reflectance Spectrometry / Laser Doppler	Limited	Can aid erythema differentiation; needs more validation

Given Imaging's PillCam series reframes the first step in many GI workflows: instead of rushing every patient into sedated endoscopy, a swallowed video capsule - typically excreted within 8–72 hours - can noninvasively visualize the esophagus, stomach, small bowel or colon and flag lesions that merit priority follow‑up, making it a pragmatic triage tool for clinics deciding who needs biopsy and who can wait for less invasive management (Magnetically guided gastric capsule endoscopy and AI lesion detection).

That triage value is exactly where AI shows promise - automated detection and characterization of gastric lesions can compress lengthy reading sessions into quick, actionable alerts - yet payers and policy reviews still caution limits: capsule systems cannot obtain tissue, and AI review of colon capsule images remains classified as experimental or unproven in coverage guidance, so capsule findings should channel patients efficiently to targeted conventional endoscopy when biopsy or therapy is required (Aetna clinical policy: capsule endoscopy indications and limitations).

For health systems assessing capsule plus AI pathways, the clear “so what” is operational: better upstream prioritization and fewer unnecessary sedated procedures, while preserving definite diagnostic steps for cases that truly need biopsy.

Use	Clinical takeaway
Diagnostic visualization (esophagus/stomach/small bowel/colon)	Noninvasive triage; helpful for obscure bleeding, Crohn's scenarios
Biopsy or therapy	Not possible with capsule; conventional endoscopy required for tissue
AI‑assisted CE reading	Promising for lesion detection, but some payers/policies list it as experimental for colon CE images

CytoReason's cell‑by‑cell computational disease models turn sprawling molecular datasets into actionable patient stratification tools that are especially relevant to Israel's drug‑development cluster: the Tel Aviv–based company (about 120 of 130 employees located in Israel) blends proprietary and public omics to define subgroups, predict responders, and prioritize biomarkers - helping trial teams shorten timelines and raise the probability of Phase‑2 success.

Its recent $80M round from investors including OurCrowd, NVIDIA, Pfizer and Thermo Fisher and an expanded collaboration with Pfizer signal real market traction for model‑driven R&D; CytoReason also promises operational speedups (BigQuery work cut query time from two minutes to 10 seconds) so teams can iterate hypotheses fast.

For Israeli biotechs and CROs running local cohorts, the practical “so what” is concrete: models that map disease tissue‑by‑tissue and suggest which patients to enroll or exclude can turn an expensive, slow trial into a focused experiment that finds signals sooner and spends less on failed cohorts - making precision medicine trials both faster and more affordable in Israel and beyond (CytoReason $80M funding announcement, CytoReason expanded collaboration agreement with Pfizer, CytoReason cell-by-cell disease modeling technology).

Metric	Value
Latest funding	$80M (OurCrowd, NVIDIA, Pfizer, Thermo Fisher)
Team (Israel)	130 employees; ~120 in Israel
Key pharma partners	Pfizer, Sanofi (and others)
Model data footprint	Grew from thousands of TB to >2.5 PB (per Google Cloud case study)

“The world understands that data alone is not enough, and that the future of data-driven insights is in data modeling. CytoReason is at the forefront of this revolution in pharma R&D.” - David Harel, Co‑founder and CEO

In Israel's highly digitized clinics and HMOs, Eleos Health's behavioral‑health AI is a practical way to slash paperwork without changing clinician workflows: the EHR‑agnostic Eleos Scribe captures live sessions or expands a few bullet points into a full, payer‑ready progress note in roughly two minutes, automatically generating over 80% of note content and cutting documentation time by more than 70% so therapists can stay focused on patients rather than after‑hours charting (Eleos Scribe automated progress notes).

Built for compliance and embedding (a lightweight browser overlay that works with web‑based EHRs), Eleos pairs session intelligence and leadership reporting with enterprise security - HITRUST, SOC 2, ISO certifications - and supports 100+ languages, making it sensible for Israel's diverse patient mix and fast clinical pilots (Eleos Health documentation for compliant note automation).

The operational payoff is simple and memorable: what used to be an evening of catch‑up becomes a two‑minute click that keeps clinicians present in the room and CQI teams confidently monitoring quality.

Metric	Value
Founded	2020
HQ	Boston, MA
Headcount	51–200
Total Funding	$68M (Series B)
Key Certifications	HITRUST CSF, SOC 2 Type 2, HIPAA, ISO 27001

“With Eleos, I am present with my clients. I'm not having to worry or be concerned about whether I'm going to miss something.”

Fairtility's CHLOE brings transparent AI into the IVF lab as a decision‑support suite that both embryologists and prospective parents can read: CHLOE EQ scores embryos across time‑lapse frames while CHLOE OQ generates an oocyte quality score from a single image, turning subjective morphology calls into standardized, auditable guidance (CHLOE embryo scoring and lab decision support).

Clinical work has shown a strong predictive link from egg to embryo - a retrospective cohort of 1,240 embryos found higher OQ aligned with better blastulation and normal fertilisation rates - which means Israeli clinics can use CHLOE to prioritize scarce lab resources, improve counseling, and give patients a real‑time view of embryo development on a mobile viewer (oocyte‑to‑embryo study and CHLOE OQ/EQ findings).

The “so what” is immediate: what used to be hours of expert review becomes a quantified score that focuses transfers, referrals for PGT, and patient conversations - helping clinics shorten time‑to‑pregnancy while keeping the lab process visible and defensible.

Metric	Value / Source
Blastocyst prediction accuracy	96% (HSFC / CHLOE EQ)
Implantation prediction accuracy	73% (HSFC / CHLOE EQ)
Avenues study cohort	1,240 embryos (Jan 2024–Jan 2025)
High‑OQ → normal 2PN fertilisation	82.3% (Avenues study)
Low‑OQ → normal 2PN fertilisation	54.6% (Avenues study)

“Coming all the way from Africa to be treated by the amazing Harley Street Fertility Clinic was the best decision ever!” - Tiana

Nucleai's section sits squarely in the multimodal wave that's reshaping clinical decision‑making: as Akira AI outlines:

enhance diagnostics, enable precision medicine, and improve patient treatment

by orchestrating agentic workflows, analytics, and prompt management to generate clinician‑ready outputs (Akira AI blog on multimodal AI in healthcare).

In an Israeli context - where tightly linked EMRs, rapid pilots and deep‑learning pathology teams are already turning weeks of review into minutes - multimodal fusion can stitch together imaging, pathology signals and clinical context into a prioritized, editable treatment draft that speeds tumor boards, trial eligibility calls, and therapy sequencing without replacing clinician judgment (local Israeli deep-learning pathology startups).

The practical payoff: draft plans that arrive polished enough for quick clinician edits, freeing time for nuanced decisions while keeping governance, security and prompt controls front‑and‑center.

Syqe's SyqeAir metered‑dose inhaler brings pharmaceutical precision to medical cannabis in Israel: clinical trials and real‑world cohorts show fast, consistent pain relief with microgram‑level Δ9‑THC dosing, markedly lower psychoactive effects than smoking or oils, and durable quality‑of‑life gains - long‑term data report ~22.8% average pain reduction, 92% of patients noting better QoL, and stable daily doses around 1,500 μg THC that are far below THC amounts consumed with traditional products (Syqe clinical trials and real‑world evidence for the SyqeAir metered‑dose inhaler).

The device's hospital use since 2015, EU‑GMP cartridge manufacturing and plans for local distribution make it especially relevant to Israeli clinics seeking controlled, titratable options; a 24‑month stability study also confirmed aerosolized THC remains within pharmaceutical dose limits over time, supporting reliable outpatient supply chains (24‑month stability trial of aerosolized THC - Journal of Cannabis Research).

The memorable payoff: one push of a pocketable inhaler and a clinician‑titrated, repeatable microdose replaces guesswork - turning an unpredictable plant into a manageable, monitorable therapy that fits Israel's evidence‑driven hospitals and HMOs.

Metric	Value / Finding
Average daily Δ9‑THC (real‑world)	~1,500 μg
Long‑term pain reduction	22.8% average; severe pain ↓28.4%
Quality of life improved	92% reported improvement
Psychoactive adverse effects	Reported in a minority (e.g., 7% in long‑term cohort)

“I inhale the dose which was personalized to me, and that corresponds with my pain, decreases the psychoactive adverse effects, and allows me to stay in focus and function properly.” - Roni Goldenberg

Practical next steps for beginners in Israel's fast-moving healthcare AI scene: start by building promptcraft and workflow skills so non‑technical staff can join clinical pilots (Nucamp's AI Essentials for Work bootcamp is a focused 15‑week option to learn those skills Register for Nucamp AI Essentials for Work - 15‑week practical AI for the workplace); pair that learning with a short study of Israel's sectoral,

“responsible innovation”

frame - the 2023 national AI policy and the Privacy Protection Authority's May 2025 draft guidelines stress transparency, data subject rights, and accountability, so plan for DPIAs, clear documentation and human‑in‑the‑loop checkpoints (White & Case Israel AI regulatory tracker - Israel AI policy overview, Nemko: AI regulation overview for Israel).

Practically: begin with low‑risk pilots that have measurable clinical endpoints, use federated or de‑identified datasets where possible, embed explainability and monitoring from day one, and partner with an HMO or academic lab for real validation; remember the blunt

“so what?”

- even a 15‑minute bedside score can change prescribing decisions, but algorithmic bias, privacy limits and unclear liability remain real hazards, so document consent, clinical validation and governance before scaling.

Next step	Why	Resource
Learn prompts & workflows	Enables non‑technical roles to run pilots	Nucamp AI Essentials for Work - 15‑week bootcamp registration
Read Israel AI policy & PPA draft	Prepare for disclosure, DPIAs and accountability	White & Case Israel AI regulatory tracker - Israel AI policy overview